IMUX Q4 2024 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$135M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$35,000

Operating Income

-$26M

Net Income

-$25M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$41M

Total Liabilities

$22M

Stockholders' Equity

$18M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$35,000	-$23,000	-52.2%
Operating Income	-$26M	-$23M	-9.6%
Net Income	-$25M	-$22M	-16.7%